Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) had its price target raised by Canaccord Genuity from $33.00 to $38.00 in a research note issued to investors on Thursday, November 9th. The brokerage currently has a hold rating on the stock.
Other equities analysts also recently issued research reports about the stock. Jefferies Group LLC lowered their target price on shares of Pacira Pharmaceuticals to $52.00 and set a buy rating for the company in a research note on Thursday, November 9th. Wedbush restated an outperform rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, August 23rd. Mizuho restated a buy rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Piper Jaffray Companies reaffirmed a buy rating and issued a $55.00 price objective on shares of Pacira Pharmaceuticals in a research report on Friday, October 27th. Finally, ValuEngine lowered shares of Pacira Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $49.71.
Shares of Pacira Pharmaceuticals (PCRX) traded up $1.85 during trading hours on Thursday, hitting $44.50. 1,010,898 shares of the company’s stock were exchanged, compared to its average volume of 845,809. Pacira Pharmaceuticals has a 1 year low of $29.81 and a 1 year high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. The business had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the business posted $0.20 EPS. equities analysts expect that Pacira Pharmaceuticals will post -0.87 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was first posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/canaccord-genuity-increases-pacira-pharmaceuticals-inc-pcrx-price-target-to-38-00/1772470.html.
In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld acquired 1,000 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was bought at an average price of $41.60 per share, with a total value of $41,600.00. Following the purchase, the director now owns 6,795 shares of the company’s stock, valued at $282,672. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP James B. Jones sold 850 shares of the company’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $41.11, for a total transaction of $34,943.50. The disclosure for this sale can be found here. In the last three months, insiders sold 69,735 shares of company stock valued at $2,692,594. Corporate insiders own 6.60% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Oppenheimer Asset Management Inc. purchased a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter valued at $114,000. Benjamin F. Edwards & Company Inc. raised its holdings in Pacira Pharmaceuticals by 12.2% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after buying an additional 303 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after buying an additional 1,752 shares during the last quarter. QS Investors LLC bought a new stake in Pacira Pharmaceuticals during the 2nd quarter valued at $157,000. Finally, Ameritas Investment Partners Inc. raised its holdings in Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after buying an additional 302 shares during the last quarter. 99.79% of the stock is owned by institutional investors.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.